Newsfeeds - Spark Newswire

3 minute read

Kronos Bio Highlights Presentation Of Preclinical Data On Its Inhibitor KB-0742 At American Association For Cancer Research Meeting

Today, 4:34 AM

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and chordoma Company

KRON

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 4:34 AM

On Monday, 524 stocks hit new 52-week lows.

AAL

22 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 4:34 AM

On Friday, 368 stocks hit new 52-week lows.

AAL

1 minute read

Piper Sandler Maintains Overweight on Kronos Bio, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 4:34 AM

Piper Sandler analyst Edward Tenthoff maintains Kronos Bio (NASDAQ:KRON) with a Overweight and lowers the price target from $50 to $30.

KRON

1 minute read

Recap: Kronos Bio Q4 Earnings

By Benzinga Insights

Today, 4:34 AM

Kronos Bio (NASDAQ:KRON) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

KRON

1 minute read

Kronos Bio Q4 EPS $(1.13) Down From $(0.70) YoY

By Benzinga Newsdesk

Today, 4:34 AM

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(1.13) per share. This is a 61.43 percent decrease over losses of $(0.70) per share from the same period last year.

KRON